Skip to main content
Equibles
OM logo

OM · Outset Medical, Inc.

Track OM — free

Use OM with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about OM

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$4.30 +0.00 (+0.00%) At close · Aug 20
Market Cap
$80.83M
Shares
18.80M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$4.30 Open$4.25 Day$4.18–4.35 52W close$3.16–15.81 Avg vol 30d133K Short int1.1M · 6.1% float · 11.0d Short vol27% Last earningsAug 6, 2026 DataMar 2025–Aug 2026 Filing10-Q · Aug 6

Raw chart and full-history price indicators begin at the captured split on Mar 20, 2025; bars on opposite sides are not compared.

Up next

Next earnings call
Nov 9, 2026 Est · unconfirmed · in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 6, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Neutral
      SellHoldBuy
      Technical Sell Momentum Very Strong Sentiment Neutral Fundamentals Fair Quant / Vol Very High
      Market backdrop VIX 14.9 · calm Equity put/call 0.52
      Technical
      price trend
      Sell
      50 / 200-day cross Golden cross
      Price vs 200-day avg −5%
      below
      Price vs 50-day avg −5%
      below
      RSI (14) 45
      neutral
      MACD trend Negative
      52-week position 9%
      near low
      Momentum
      relative strength
      Very Strong
      1-month return +2%
      trailing
      6-month return +23%
      trailing
      YTD return +16%
      this year
      Relative strength +12%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) Golden cross
      50d $5 › 200d $5 — 50d above 200d
      Institutional flow Distributing
      -7% holders QoQ · +19 funds added
      Insider flow Distributing
      Net -$133.9K over 90 days · 100% sells
      Short interest Falling
      6.08% of float · ▼ -6.1% MoM · 11.0 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      93 holders — mid 3-yr range
      Squeeze score 67
      elevated · 0–100
      Fundamentals
      Fair
      Revenue growth +5%
      Y/Y
      Gross margin 39%
      expanding
      EPS growth +85%
      Y/Y
      Free cash flow $-47.1M
      Balance sheet $66.0M
      net debt
      Quant / Vol
      risk profile
      Very High
      Volatility 101%
      annualized · 1-yr
      Max drawdown −80%
      past year
      ATR 8.9%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Beat or met 2 of last 3
      Latest guidance · from the 8-K filed Aug 6, 2026
      Revenue · full year 2026 Initiated $125M – $130M
      prior FY $119.48M midpoint +6.7% Y/Y
      Prior guidance period ended · from the 8-K filed Nov 10, 2025
      2025 revenue · 2025 $115M – $120M
      Cash use · 2025 up to $50M
      Guided vs delivered · last 3 settled
      2025 revenue 2025
      guided $115M – $120M
      $119.48M In line
      Revenue full year 2024
      guided $145M – $153M
      $113.69M Miss −23.7%
      Revenue 2023
      guided $130M
      $130.38M Beat +0.3%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Sell
      4 · 1 · 1
      50 / 200-day cross
      Golden cross Bullish
      Price vs 200-day avg
      −5% Bearish
      Price vs 50-day avg
      −5% Bearish
      RSI (14)
      45 Neutral
      MACD trend
      Negative Bearish
      52-week position
      9% Bearish
      Market signals — smart money & positioning
      Mixed
      Trend (MA cross) Golden cross
      50d $5 › 200d $5 — 50d above 200d
      Institutional flow Distributing
      -7% holders QoQ · +19 funds added
      Insider flow Distributing
      Net -$133.9K over 90 days · 100% sells
      Short interest Falling
      6.08% of float · ▼ -6.1% MoM · 11.0 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      93 holders — mid 3-yr range
      Price context
      position in its 52-week range
      Range low $3 Now $4 · 9% Range high $16
      vs 200-day avg -5% vs 50-day avg -5% 50-day above 200-day golden cross

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Non-GAAP general and administrative expense non-GAAP 17.13M Six Months Ended June 30, 2026 —
      Non-GAAP gross profit non-GAAP 25.57M Six Months Ended June 30, 2026 —
      Non-GAAP net loss per share, diluted non-GAAP -$1.63 Six Months Ended June 30, 2026 —
      Non-GAAP net loss, diluted non-GAAP -30.15M Six Months Ended June 30, 2026 —
      Non-GAAP research and development expense non-GAAP 9.65M Six Months Ended June 30, 2026 —
      Non-GAAP sales and marketing expense non-GAAP 24.56M Six Months Ended June 30, 2026 —
      Non-GAAP total operating expense non-GAAP 51.35M Six Months Ended June 30, 2026 —
      Total cash, including restricted cash, cash equivalents and short-term investments $151M Q2 2026 —
      Gross margin 39.1% FY2025 —
      Net cash used in operations $46M FY2025 —
      Recurring revenue $88.7M FY2025 —
      Total cash, including restricted cash, cash equivalents and investment securities $172.8M FY2025 —
      Year-end cash, including restricted cash, cash equivalents and short-term investments $173M Q4 2025 —
      Cumulative treatments on Tablo 3M Exiting 2025 —
      Sites of care that have insourced dialysis with Outset 1,000 Exiting 2025 —
      Treatments performed per year 1M Exiting 2025 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Medical Devices — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      OM
      Outset Medical, Inc.
      this stock
      		$80.83M +15.9% +5.1% — 6.1%
      ABT
      Abbott Laboratories
      		 $198.81B -8.9% +5.7% 32.0 1.3%
      SYK
      Stryker Corp
      		 $127.26B -6.8% +11.2% 34.4 2.2%
      MDT
      Medtronic plc
      		 $120.49B -3.9% +8.4% 25.2 1.4%
      BSX
      Boston Scientific Corp
      		 $71.55B -48.2% +12.5% 20.4 1.5%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      93
      % held
      74.3%
      Net QoQ
      -1.6M sh
      Top holder
      FMR LLC
      Held Float
      View
      Held by Funds
      Fund positions
      97
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      1.1M
      Days to cover
      11.0d
      Change
      -74.3K sh
      View
      Short Volume
      Short vol %
      27%
      As of
      Aug 20, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      749
      Value
      $3.5K
      As of
      Jul 29, 2026
      View
      Off-Exchange
      Off-exchange %
      39.7%
      Week of
      Jul 13, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$133.9K
      Buyers / Sellers
      0 / 3
      Buyers Sellers
      View
      Financials
      Financials
      Revenue (FY)
      $119.5M
      Net income (FY)
      $-81.7M
      EPS diluted
      $-5.37
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 6, 2026
      This year
      12
      View
      Proposed Sales
      Value
      $19.9K
      Shares
      4.4K
      Filed
      Aug 14, 2026
      View
      Exempt Offerings
      Offering
      $3.9M
      Filed
      Jan 21, 2025
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 6, 2026
      View

      Performance

      Raw-price comparisons begin at the captured split on Mar 20, 2025; windows that need an earlier baseline remain unavailable.

      5D 20D 120D MTD YTD
      OM +1.2% +1.7% +23.2% -5.9% +15.9%
      SPY -2.0% +3.3% +11.2% +2.1% +11.8%
      vs SPY +3.1% -1.7% +12.0% -8.0% +4.1%
      Key facts CIK 1484612 CUSIP 690145206 13F (30d) 89 filings 83 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)